证券代码：300402 证券简称：宝色股份 公告编号：2026-003 南京宝色股份公司 2026年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会召开期间没有增加、否决或变更议案情况发生； 2、本次股东会不涉及变更前次股东会决议； 3、本次股东会采取现场投票和网络投票表决相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召集人：南京宝色股份公司（以下简称"公司"）董事会 2、会议召开的日期、时间 现场会议召开时间：2026 年 3 月 31 日（星期二）14:00 4、会议召开方式：本次股东会采取现场表决与网络投票相结合的方式召开。公 司现场会议同时提供了通讯参会方式。 5、会议主持人：公司董事长薛凯先生因外出参会无法现场出席并主持会议，根 据《公司章程》的有关规定，由过半数董事共同推举公司董事、总经理刘鸿彦先生 主持本次会议。 6、会议召开的合法、合规性：本次股东会的召集、召开程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 1 （二）会议出席情况 1、股东出 ...

地址：中国.西安曲江雁南五路曲江影视大厦六层、七层、二十五层 电话:(029)68206166 传真:(029)68206135 陕西稼轩律师事务所 关于 南京宝色股份公司 2026 年第一次临时股东会之 法律意见书 二〇二六年三月 地址：中国.西安曲江雁南五路曲江影视大厦六层、七层、二十五层 电话:(029)68206166 传真:(029)68206135 关于南京宝色股份公司 2026 年第一次临时股东会法律意见书 致：南京宝色股份公司（以下简称"公司"） 陕西稼轩律师事务所（以下简称"本所"）接受公司的委托，指 派律师对公司 2026 年第一次临时股东会（以下简称"本次会议"或 "本次股东会"）的合法性进行见证，并根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下 简称"《证券法》"）《上市公司股东会规则》（以下简称"《股东 会规则》"）等现行有效的法律、行政法规、规章、规范性文件及《南 京宝色股份公司章程》（以下简称"《公司章程》"）的规定，就本 次会议的召集与召开程序、召集人资格、出席会议人员资格、会议表 决程序及表决结果等事宜，出具本法律意见书。 为出具本法律 ...

证券代码：300402 证券简称：宝色股份 公告编号：2026-002 南京宝色股份公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、会议召集人：公司董事会 公司第六届董事会第十七次会议审议通过了《关于适时召开公司2026年第一次 临时股东会的议案》。公司董事会授权董事长择机确定公司2026年第一次临时股东 会的召开时间、股权登记日等具体事项。 3、会议召开的合法、合规性：本次会议的召集、召开符合《中华人民共和国公 司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第2号—创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文 件及《公司章程》的有关规定。 4、会议时间： （1）现场会议日期时间：2026年3月31日（星期二）14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为2026 年3月31日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互 ...

Group 1 - The core viewpoint of the articles indicates that Baose Co., Ltd. (300402) has experienced stock price fluctuations and varying capital flows in the recent week from February 7 to February 13, 2026 [1] - On February 12, the stock price showed active performance during the trading session, but the overall increase was minimal [1] - There were no significant announcements or events from the company, with recent dynamics primarily driven by market trading [1] Group 2 - As of February 13, 2026, Baose's latest stock price was 22.06 yuan, with a cumulative increase of 0.09% over the past five days and a price fluctuation of 4.67% [2] - On February 12, the closing price was 22.10 yuan, reflecting a single-day increase of 0.78%, while on February 11, it closed at 21.93 yuan, showing a decrease of 0.68% [2] - The stock is currently in a volatile pattern, with a 20-day Bollinger Band resistance level at 24.75 yuan and a support level at 20.75 yuan [2] Group 3 - On February 12, there was a net inflow of 238.55 million yuan from major funds, but this shifted to a net outflow of 1,049.77 million yuan on February 13, indicating short-term capital divergence [2] - Retail investor participation was relatively high, with retail inflow accounting for 37% on February 13 [2] - Technical indicators show that the MACD histogram remains negative, and the KDJ indicator's K line is at 38.49, indicating a neutral market sentiment [2] - Trading volume has decreased compared to previous periods, with a turnover rate of 1.40% on February 13 [2]

Group 1 - The core point of the article is that Shanxi Huaxin Hai Trading Co., Ltd. has announced a reduction in its shareholding in Baose Co., Ltd. through a centralized bidding process [1] - The reduction involves a total of 2,460,000 shares, which accounts for 0.9968% of the company's total share capital [1] - The average price for the shares sold was 22.63 yuan per share, amounting to approximately 55.67 million yuan [1] Group 2 - After the reduction, Shanxi Huaxin Hai holds 13,320,000 shares in Baose Co., Ltd., with its shareholding percentage decreasing from 6.3941% to 5.3973% [1]

Core Viewpoint - The medical titanium alloy industry is experiencing significant growth driven by an aging population and increasing chronic disease rates, leading to higher demand for medical devices and implants. The market size for medical titanium alloys in China is projected to reach 4.32 billion yuan in 2024, reflecting a 9% year-on-year increase [1][6]. Group 1: Industry Overview - Medical titanium alloys are specialized biocompatible materials used for manufacturing human implants, characterized by excellent biocompatibility, high specific strength (over 300 MPa·cm³/g), and moderate elastic modulus (approximately 110 GPa) [3]. - The development of medical titanium alloys has progressed through three generations, with the latest generation focusing on reducing toxicity and improving compatibility with human bone [3][4]. Group 2: Market Size and Growth - The market for medical titanium alloys is expected to continue growing, with the orthopedic implant sector (including artificial joints and spinal correction devices) holding the largest market share at 50%, projected to reach 2.16 billion yuan in 2024 [6]. - Factors driving demand in the orthopedic implant sector include an aging population (over 300 million people aged 60 and above in China), advancements in medical technology, and supportive policies [6]. Group 3: Competitive Landscape - The medical titanium alloy industry features a concentrated head with leading companies like Baotai Co., West Superconductor, and Xiangtou Jintian dominating the mid-to-high-end market, while smaller firms focus on niche segments to avoid direct competition [7]. - Key players in the industry include Jiangsu Tiangong Technology Co., Baotai Co., and others, with a focus on R&D and production of titanium and titanium alloy materials [7][8]. Group 4: Industry Trends - The industry is moving towards functional upgrades of materials to meet diverse clinical needs, emphasizing the development of new alloys that are aluminum and vanadium-free for enhanced biocompatibility [9]. - Integration of smart technologies into titanium alloy products is becoming a significant innovation direction, with the incorporation of micro-sensors for real-time monitoring of implant conditions [10]. - The industry is accelerating its green and low-carbon transformation, focusing on energy-efficient production processes and recycling systems for titanium alloy materials to reduce waste and production costs [11].

证券代码：300402 证券简称：宝色股份 公告编号：2026-001 南京宝色股份公司 | 基本情况 1. | | | | --- | --- | --- | | | 信息披露义务人 | 山西华鑫海贸易有限公司 | | | 住所 | 山西综改示范区太原学府园区龙兴街192号1幢4层403室 | | | 权益变动时间 | 2026年1月19日至2026年1月21日 | | | 权益变动过程 | 山西华鑫海因资金需求于2026 年 1月 19 日至 2026 年 1 月 | | | 21 | 日期间，通过深圳证券交易所交易系统以集中竞价方式累计减持公 | 一、股东减持股份触及 1%整数倍的情况 1 | | 司股份2,460,000股，占公司总股本的0.9968%。本次减持后，山西华 | | | | | --- | --- | --- | --- | --- | | | 鑫海持有本公司的股份由15,780,000股减少至13,320,000股，占公司 | | | | | | 总股本的比例由6.3941%减少至5.3973%，减持股份比例触及1%的整 | | | | | 数倍。 | | | | | | | 截至本公 ...

Group 1 - The core point of the article is that Baose Co., Ltd. reported a total of 28,238 shareholders as of January 20, 2026 [2]

Core Viewpoint - Baose Co., Ltd. focuses on the research, design, manufacturing, and sales of special materials non-standard pressure vessel equipment, primarily involving titanium, zirconium, nickel, and high-grade stainless steel, with applications across various industries [1] Company Overview - The company specializes in non-standard pressure vessel equipment made from special materials, including heat exchangers, towers, reactors, and pipeline fittings [1] - Its products are widely used in chemical, energy, metallurgy, electric power, environmental protection, shipbuilding, and marine engineering sectors [1] Industry Context - The company is positioned as a professional supplier in the domestic special materials non-standard equipment manufacturing field [1] - With the ongoing transformation of the national energy industry and the deepening of the "dual carbon" strategy, the company aims to expand into new business areas [1] - The continuous expansion of downstream application fields for special materials non-standard pressure vessel equipment is expected to drive the company's growth towards new productive forces [1]

Group 1: Company Announcements - Zhongwei Company plans to acquire 64.69% equity of Hangzhou Zhonggui through a combination of share issuance and cash payment, aiming to enhance its capabilities in CMP equipment and solutions [1] - Lixun Precision intends to repurchase shares worth between 1 billion to 2 billion RMB for employee stock ownership plans or equity incentives, with a maximum repurchase price of 86.96 RMB per share [2] - ZaiJing Pharmaceutical has reached a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, receiving an upfront payment of 100 million USD [3] - Tianci Materials expects a net profit increase of 127% to 231% for 2025, driven by significant growth in lithium-ion battery material sales [4] - Meike Home plans to acquire 100% equity of Shenzhen Wande Technology through share issuance and cash payment, with stock resuming trading on January 5, 2026 [6][7] - ST KeliDa is planning a change in control, with stock suspension starting January 5, 2026, due to the transfer of 100% equity of its controlling shareholder [8] - Xinzhou Bang intends to invest approximately 260 million USD in a lithium-ion battery materials project in Saudi Arabia, enhancing its global capacity and supply chain [9] Group 2: Financial Performance - Kid's King anticipates a net profit increase of 51.72% to 82.06% for 2025 [9] - Guangku Technology expects a net profit growth of 152% to 172% for 2025 [9] Group 3: Mergers and Acquisitions - Xidi Micro plans to acquire 100% equity of Chengxin Micro for 310 million RMB [9] - Haili Biological's subsidiary intends to acquire 51% equity of seven dental chain companies for 61.2 million RMB [9]